Swiss National Bank’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.32M | Buy |
722,000
+39,600
| +6% | +$300K | ﹤0.01% | 1305 |
|
|
2026
Q1 | $5.23M | Buy |
682,400
+30,000
| +5% | +$205K | ﹤0.01% | 1345 |
|
|
2025
Q4 | $1.29M | Buy |
652,400
+138,900
| +27% | +$315K | ﹤0.01% | 2066 |
|
|
2025
Q3 | $1.26M | Buy |
513,500
+92,000
| +22% | +$237K | ﹤0.01% | 2063 |
|
|
2025
Q2 | $1.11M | Buy |
421,500
+11,100
| +3% | +$29.8K | ﹤0.01% | 2099 |
|
|
2025
Q1 | $1.24M | Buy |
410,400
+136,400
| +50% | +$413K | ﹤0.01% | 2038 |
|
|
2024
Q4 | $701K | Buy |
274,000
+4,000
| +1% | +$16.7K | ﹤0.01% | 2342 |
|
|
2024
Q3 | $1M | Buy |
270,000
+6,900
| +3% | +$31.9K | ﹤0.01% | 2216 |
|
|
2024
Q2 | $1.66M | Hold |
263,100
| – | – | ﹤0.01% | 1910 |
|
|
2024
Q1 | $1.41M | Hold |
263,100
| – | – | ﹤0.01% | 2036 |
|
|
2023
Q4 | $1.32M | Sell |
263,100
-21,500
| -8% | -$67.5K | ﹤0.01% | 2088 |
|
|
2023
Q3 | $481K | Hold |
284,600
| – | – | ﹤0.01% | 2516 |
|
|
2023
Q2 | $791K | Buy |
284,600
+25,400
| +10% | +$71.8K | ﹤0.01% | 2413 |
|
|
2023
Q1 | $472K | Sell |
259,200
-30,800
| -11% | -$95.8K | ﹤0.01% | 2537 |
|
|
2022
Q4 | $1.47M | Buy |
290,000
+8,900
| +3% | +$48.9K | ﹤0.01% | 2089 |
|
|
2022
Q3 | $1.4M | Hold |
281,100
| – | – | ﹤0.01% | 2119 |
|
|
2022
Q2 | $1.05M | Buy |
281,100
+93,100
| +50% | +$374K | ﹤0.01% | 2335 |
|
|
2022
Q1 | $1.05M | Buy |
188,000
+15,900
| +9% | +$97.5K | ﹤0.01% | 2380 |
|
|
2021
Q4 | $1.05M | Buy |
172,100
+2,500
| +1% | +$18.8K | ﹤0.01% | 2455 |
|
|
2021
Q3 | $1.65M | Buy |
169,600
+85,500
| +102% | +$941K | ﹤0.01% | 2170 |
|
|
2021
Q2 | $1.2M | Buy |
84,100
+9,600
| +13% | +$159K | ﹤0.01% | 2396 |
|
|
2021
Q1 | $1.77M | Buy |
74,500
+1,300
| +2% | +$33.7K | ﹤0.01% | 2076 |
|
|
2020
Q4 | $976K | Buy |
+73,200
| New | +$704K | ﹤0.01% | 2296 |
|
|
2017
Q2 | – | Sell |
-42,450
| Closed | -$151K | – | 2565 |
|
|
2017
Q1 | $151K | Hold |
42,450
| – | – | ﹤0.01% | 2523 |
|
|
2016
Q4 | $243K | Hold |
42,450
| – | – | ﹤0.01% | 2535 |
|
|
2016
Q3 | $330K | Hold |
42,450
| – | – | ﹤0.01% | 2465 |
|
|
2016
Q2 | $264K | Buy |
42,450
+6,100
| +17% | +$47.4K | ﹤0.01% | 2531 |
|
|
2016
Q1 | $289K | Buy |
36,350
+6,450
| +22% | +$60.8K | ﹤0.01% | 2502 |
|
|
2015
Q4 | $518K | Buy |
+29,900
| New | +$444K | ﹤0.01% | 2241 |
|
Other funds holding IBRX
Swiss National Bank's IBRX Position: Q2 2026 in Review
Swiss National Bank increased its ImmunityBio (IBRX) stake by 5.8% in Q2 2026, buying an estimated $300K and bringing the position to 722,000 shares worth $6.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1305.
Swiss National Bank first reported a position in IBRX in Q4 2015 and has held it in 29 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.
- Swiss National Bank held 722,000 shares of ImmunityBio worth $6.32M as of Q2 2026.
- Swiss National Bank bought 39,600 ImmunityBio shares in Q2 2026, an estimated $300K.
- ImmunityBio made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1305 holding.
- Swiss National Bank first reported a position in ImmunityBio in Q4 2015 and has held it in 29 quarters since.
- 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.
Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.